In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug

You may also be interested in...



As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?

MUMBAI - Leading Indian doctors have begun speaking out against GlaxoSmithKline's anti-diabetes brand Avandia (rosiglitazone) - branded as Windia in the Indian market - after U.S.FDA restricted the drug's use and European regulatory authorities ordered a complete withdrawal of the medicine from the market

India's DCGI Halts Avandia's TIDE Trial Aimed At Proving CV Safety; Steps Up Review of "Controversial Drugs" Sold In India

MUMBAI - GlaxoSmithKline may be temporarily relieved after U.S. FDA's joint advisory committee recommended that GSK's controversial anti-diabetes drug Avandia (rosiglitazone) remain on the market; but dealing with the product seems to be getting tougher for the company in countries like India

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC073235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel